HIV整合酶抑制剂药物及其专利研究  

HIV integrase inhibitor drugs and its patent research

作　　者：黄璐 陆毅 王卫彬 薛琦 HUANG Lu;LU Yi;WANG Wei-bin;XUE Qi(Guangzhou Wellhealth Bio-pharma Co.,Ltd.,Guangzhou 510200,China;Shanghai Beshining Law Office,Shanghai 200032,China;Wuhan Xinghua Wisdom Pharma-tech Co.,Ltd.,Wuhan 430075,China)

机构地区：[1]广州丹康医药生物有限公司,广州510200 [2]上海弼兴律师事务所,上海200032 [3]武汉兴华智慧医药科技有限公司,武汉430075

出　　处：《中国新药杂志》2018年第19期2214-2220,共7页Chinese Journal of New Drugs

摘　　要：本文通过Cortellis等数据库对国内外HIV整合酶抑制剂的上市情况、研发进展、已上市药物专利情况进行了检索与分析,重点对已上市HIV整合酶抑制剂药物在中国的专利(如化合物、晶型、制备工艺及中间体、药物制剂、药物组合物、药物新用途等方面的专利)进行了详细的解读与分析,以期为国内医药企业开发HIV整合酶抑制药物提供专利信息,为其合理利用专利信息进行项目立项评估、技术方案设计、专利挖掘与布局,甚至专利挑战等提供参考依据。This paper searched and analysed the listing situation,development and pharmaceutical patents of HIV integrase inhibitors through Cortellis databases and other databases. Especially,the paper focused on the patents of drugs already on the market in China,such as the patents of compound,crystalline,preparation process and intermediate,formulation,drug combination,and drugs new use,in order to provide patent information for domestic pharmaceutical companies to develop HIV integrase inhibitors. It also provided references for their rational use of patent information,such as project evaluation,technical plan design,patent layout,and even patent challenges.

关 键 词：HIV整合酶抑制剂 专利研究 拉替拉韦 多替拉韦 艾维雷韦 

分 类 号：R95[医药卫生—药学]